Menu Search
Equities

I-Mab

0VY:DUS

I-Mab

Actions
  • Price (EUR)1.01
  • Today's Change0.045 / 4.66%
  • Shares traded220.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 11:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.

  • Revenue in USD (TTM)--
  • Net income in USD--
  • Incorporated2016
  • Employees220.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.